Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA Of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta. of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.

Abstract: Vaccines and therapeutic compositions and methods for their production and use against Herpes Simplex Virus (HSV) are provided employing recombinant HSV glycoproteins B and D.The following E. coli HB101 strains were deposited at the A.T.C.C., where the plasmid indicates the plasmid employed to transform the strain; pHS203; pHS112; pHS114; pHS127A and pHS206 were deposited on Apr. 4, 1984, and assigned Accession Nos. 39649-39653, respectively; pYHS109 and pYHS118 were deposited on Jul. 11, 1984, and given Accession Nos. 39762 and 39763, respectively.

Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.

Abstract: The present invention relates to methods for using IGF as inhibitors of inflammatory response, ischemic injury, and organ rejection.

Abstract: Compositions which are useful for treatment of individuals for Herpes Simplex Virus (HSV) infections are provided, as are methods for their use. These compositions are comprised of immunogenic polypeptides which are comprised of an epitope of HSV VP16; they may also be comprised of an epitope of an HSV glycoprotein. Also provided are polypeptides which are used in the compositions for treating individuals for HSV infection, and methods and compositions used in the production of the polypeptides.

Abstract: The present invention relates to methods for using IGF as inhibitors of inflammatory response, ischemic injury, and organ rejection.

Abstract: A vaccine composition, comprising an antigenic substance in association with a liposome and an oil-in-water emulsion comprising a muramyl peptide, a metabolizable oil, and optionally an additional emulsifying agent. The two components of the adjuvant (i.e., the liposome/antigen component and the emulsion component) act together to produce high levels of immune response.

Abstract: Methods and compositions are provided for the production of human superoxide dismutase and a novel protocol for enhancing efficiency of expression. The gene encoding for human superoxide dismutase is isolated and inserted into a vector in conjunction with a synthetic linker which provides for enhanced efficiency in translation. E. coli strain D1210 (pSODX8) was deposited at the A.T.C.C. on Sep. 27, 1983 and given Accession No. 39453. Yeast strain 2150-2-3 (pC1/1GAPSOD) and E. coli strains D1210 (pSOD11) and D1210 (pS2OR) were deposited at the A.T.C.C. on May 9, 1984, and given Accession Nos. 20708, 39679 and 39,680, respectively.

Abstract: Methods and compositions are provided for the production of human superoxide dismutase and a novel protocol for enhancing efficiency of expression. The gene encoding for human superoxide dismutase is isolated and inserted into a vector in conjunction with a synthetic linker which provides for enhanced efficiency in translation.

Abstract: Disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the DNA sequence for HSV-2 glycoprotein G (gG) or fragments of said gG sequence particularly by the unique sequence for gG or portions of said unique sequence. The unique sequence proteins and polypeptides are serologically active, can be produced easily and safely at low cost, are useful as diagnostic reagents for HSV-2 and as vaccines against HSV-2. Further disclosed are serological assays based on such unique sequence gG proteins and polypeptides that diagnose the presence of herpes simplex virus type 2 (HSV-2) specific antibodies and can differentiate between HSV-2 and herpes simplex virus type 1 (HSV-1) specific antibodies. Such assays are useful to diagnose genital infections, to detect for exposure to HSV-2 and to screen pregnant women to protect newborns from neonatal HSV-2 infection.

Abstract: Cell lines are provided that produce improved neutralizing monoclonal antibodies reactive with human cachectin. The antibodies have various therapeutic and diagnostic uses.

Abstract: Methods and compositions are provided for producing, in yeast, basic and acidic fibroblast growth factors (FGF's) that are at least partially acetylated at their amino-termini. DNA constructs containing genes coding for the FGF polypeptides under transcriptional control of a regulatable promoter are expressed in transformed host yeast cells to achieve high yields of the processed FGF's.

Abstract: Disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the DNA sequence for HSV-2 glycoprotein G (gG) or fragments of said gG sequence, particularly by the unique sequence for gG or portions of said unique sequence. The unique sequence proteins and polypeptides are serologically active, can be produced easily and safely at low cost, are useful as diagnostic reagents for HSV-2 and as vaccines against HSV-2. Further disclosed are serological assays based on such unique sequence gG proteins and polypeptides that diagnose the presence of herpes simplex virus type 2 (HSV-2) specific antibodies and can differentiate between HSV-2 and herpes simplex virus type 1 (HSV-1) specific antibodies. Such assays are useful to diagnose genital infections, to detect for exposure to HSV-2 and to screen pregnant women to protect newborns from neonatal HSV-2 infection.

Abstract: The glycoprotein B ("gB") and analogs thereof are provided by recombinant DNA technology. Oligonucleotide sequences are provided coding the glycoprotein, its precursor and fragments thereof. Methods and compositions are disclosed for the production of the glycoprotein and analogous proteins as well as oligonucleotide sequences, which may be used for probes or other applications, and particularly may be used for vaccines.

Abstract: A composition for the treatment of osteoporosis and the method of treatment of osteoporosis therewith in mammals is disclosed. The method comprises administering Insulin-Like Growth Factor I (IGF-I) to a mammal in need thereof. Need is determined by bone mineral density levels, whether by single measurement (as compared to the population generally) or by a series of measurements evidencing a loss of bone mineral density, or due to a genetic or familial or other predisposition to bone mineral density loss.

Abstract: Efficient integration of heterologous DNA into yeast genomic DNA is accomplished at high copy number by targeting integration vectors to dispersed repetitive elements such as DELTA sequences, Ty elements, or tRNA DNA sequences present in the host cell genome.

Abstract: Vaccines against Herpes Simplex virus containing recombinant polypeptides which are cross-reactive with glycoprotein D of the virus, methods for their production using recombinant DNA techniques in yeast, and methods for the use of the vaccine are provided. E. coli strains HB101 containing plasmids pYHS 109 and pYHS118 were deposited at the American Type Culture Collection on Jul. 11, 1984, and granted accession nos. 39762 and 39763, respectively.

Abstract: DNA encoding two forms of PDGF A-chain polypeptide, the construction of expression vectors for expressing such DNA in yeast and mammalian cells, and the expression of such DNA in yeast and mammalian cells to produce active PDGF A-chain homodimer and active PDGF A-chain/B-chain heterodimer are disclosed.

Abstract: A yeast .alpha.-factor expression system is provided comprised of a truncated leader sequence, containing the .alpha.-factor signal peptide and one glycosylation site, linked by a processing site to a non-yeast protein-encoding sequence.

Abstract: The present invention provides recombinant polypeptides derived from CMV glycoprotein gB and truncated fragments thereof which contain at least one epitope which is immunologically identifiable with one encoded by the CMV genome. The complete characterization of the gB protein, including the identity of glycoprotein gp55, permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. This invention provides recombinant polypeptides and recombinant polynucleotides encoding these polypeptides wherein a neutralizing epitope of gB is localized within gp55.